Published in Blood on April 01, 1988
Unraveling a cytoplasmic role for hnRNP D in the in vivo mRNA destabilization directed by the AU-rich element. Genes Dev (1999) 3.59
A role of the latent TGF-beta 1-binding protein in the assembly and secretion of TGF-beta 1. EMBO J (1991) 2.73
A phorbol ester-regulated ribonuclease system controlling transforming growth factor beta 1 gene expression in hematopoietic cells. Mol Cell Biol (1990) 1.17
Negative regulation of globin gene expression during megakaryocytic differentiation of a human erythroleukemic cell line. Mol Cell Biol (1991) 1.07
Gene expression of TPA induced differentiation in HL-60 cells by DNA microarray analysis. Nucleic Acids Res (2002) 1.01
Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med (1987) 13.50
Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature (1983) 8.18
Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med (2001) 7.88
Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med (2001) 7.78
Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci U S A (1995) 7.11
Homogeneously staining chromosomal regions contain amplified copies of an abundantly expressed cellular oncogene (c-myc) in malignant neuroendocrine cells from a human colon carcinoma. Proc Natl Acad Sci U S A (1983) 7.01
Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet (2001) 6.82
Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science (1997) 6.37
A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J (1996) 5.33
Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. Science (1998) 5.07
Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. Am J Pathol (1999) 5.02
Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation (1992) 4.96
Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J (2001) 4.70
Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma. Proc Natl Acad Sci U S A (1999) 4.52
Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat Med (2001) 4.50
Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci U S A (1998) 4.48
Clinical applications of angiogenic growth factors and their inhibitors. Nat Med (1999) 4.26
Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J (1997) 4.07
Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3. EMBO J (2001) 3.88
Identification of nuclear proteins encoded by viral and cellular myc oncogenes. Nature (1984) 3.86
PDGF-C is a new protease-activated ligand for the PDGF alpha-receptor. Nat Cell Biol (2000) 3.81
Vascular endothelial growth factor C induces angiogenesis in vivo. Proc Natl Acad Sci U S A (1998) 3.72
Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema. Nat Genet (2000) 3.66
A cellular oncogene (c-Ki-ras) is amplified, overexpressed, and located within karyotypic abnormalities in mouse adrenocortical tumour cells. Nature (1983) 3.56
Selective radioactive labeling of cell surface sialoglycoproteins by periodate-tritiated borohydride. J Biol Chem (1977) 3.50
Growth suppression by Lkb1 is mediated by a G(1) cell cycle arrest. Proc Natl Acad Sci U S A (1999) 3.46
Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res (2001) 3.38
FGFR-4, a novel acidic fibroblast growth factor receptor with a distinct expression pattern. EMBO J (1991) 3.19
The receptor tyrosine kinase TIE is required for integrity and survival of vascular endothelial cells. EMBO J (1995) 3.16
Altered cell cycle kinetics, gene expression, and G1 restriction point regulation in Rb-deficient fibroblasts. Mol Cell Biol (1996) 3.15
VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am J Pathol (1999) 3.09
Endothelial receptor tyrosine kinases involved in angiogenesis. J Cell Biol (1995) 3.06
Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO J (2001) 3.00
Vascular abnormalities and deregulation of VEGF in Lkb1-deficient mice. Science (2001) 2.99
Ornithine decarboxylase activity is critical for cell transformation. Nature (1992) 2.92
Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA (1988) 2.89
Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma. Am J Pathol (2001) 2.89
A model for gene therapy of human hereditary lymphedema. Proc Natl Acad Sci U S A (2001) 2.88
Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells. J Biol Chem (1994) 2.87
Association of Cdk-activating kinase subunits with transcription factor TFIIH. Nature (1995) 2.87
K562--a human erythroleukemic cell line. Int J Cancer (1979) 2.84
Vascularization of the mouse embryo: a study of flk-1, tek, tie, and vascular endothelial growth factor expression during development. Dev Dyn (1995) 2.83
VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development. Development (1996) 2.82
Pulmonary vascular endothelial growth factor and Flt-1 in fetuses, in acute and chronic lung disease, and in persistent pulmonary hypertension of the newborn. Am J Respir Crit Care Med (2001) 2.76
Induction of a basement membrane glycoprotein in embryonic kidney: possible role of laminin in morphogenesis. Proc Natl Acad Sci U S A (1980) 2.74
Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc Natl Acad Sci U S A (1996) 2.71
PDGF-D is a specific, protease-activated ligand for the PDGF beta-receptor. Nat Cell Biol (2001) 2.70
Repression of cyclin D1: a novel function of MYC. Mol Cell Biol (1994) 2.67
Nucleotide sequence to the v-myc oncogene of avian retrovirus MC29. Proc Natl Acad Sci U S A (1983) 2.66
Induction of erythroid differentiation in the human leukaemia cell line K562. Nature (1979) 2.64
Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation. Cancer Res (2000) 2.64
Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res (2000) 2.63
Lymphatic endothelium and Kaposi's sarcoma spindle cells detected by antibodies against the vascular endothelial growth factor receptor-3. Cancer Res (1998) 2.60
BRCT domain-containing protein TopBP1 functions in DNA replication and damage response. J Biol Chem (2001) 2.60
Oncogene amplification in tumor cells. Adv Cancer Res (1986) 2.44
Fibronectin is produced by human macrophages. J Exp Med (1980) 2.44
Requirement for TFIIH kinase activity in transcription by RNA polymerase II. Nature (1995) 2.43
VEGF and VEGF-C: specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane. Dev Biol (1997) 2.43
The apoptotic v-cyclin-CDK6 complex phosphorylates and inactivates Bcl-2. Nat Cell Biol (2000) 2.36
A novel endothelial cell surface receptor tyrosine kinase with extracellular epidermal growth factor homology domains. Mol Cell Biol (1992) 2.34
Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc Natl Acad Sci U S A (1998) 2.32
Proinflammatory cytokines regulate expression of the lymphatic endothelial mitogen vascular endothelial growth factor-C. J Biol Chem (1998) 2.28
VEGFs, receptors and angiogenesis. Semin Cancer Biol (1999) 2.25
Vascular endothelial growth factor receptor-3 in lymphangiogenesis in wound healing. Am J Pathol (2000) 2.24
Allograft response in vitro. Transplant Rev (1972) 2.20
Interaction of endostatin with integrins implicated in angiogenesis. Proc Natl Acad Sci U S A (2001) 2.19
Isolation of the pericellular matrix of human fibroblast cultures. J Cell Biol (1979) 2.19
The human p50csk tyrosine kinase phosphorylates p56lck at Tyr-505 and down regulates its catalytic activity. EMBO J (1992) 2.16
A role for estrogen receptor beta in the regulation of growth of the ventral prostate. Proc Natl Acad Sci U S A (2001) 2.12
VEGF-C and VEGF-D expression in neuroendocrine cells and their receptor, VEGFR-3, in fenestrated blood vessels in human tissues. FASEB J (2000) 2.06
Tie receptors: new modulators of angiogenic and lymphangiogenic responses. Nat Rev Mol Cell Biol (2001) 2.05
FLT4 receptor tyrosine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines. Cancer Res (1992) 1.99
A recombinant mutant vascular endothelial growth factor-C that has lost vascular endothelial growth factor receptor-2 binding, activation, and vascular permeability activities. J Biol Chem (1998) 1.98
Lack of lymphatic vascular specificity of vascular endothelial growth factor receptor 3 in 185 vascular tumors. Cancer (1999) 1.97
Biological action of angiopoietin-2 in a fibrin matrix model of angiogenesis is associated with activation of Tie2. Cardiovasc Res (2001) 1.95
A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J (1996) 1.95
Biosynthesis of vascular endothelial growth factor-D involves proteolytic processing which generates non-covalent homodimers. J Biol Chem (1999) 1.94
Biosynthesis of two subunits of type IV procollagen and of other basement membrane proteins by a human tumor cell line. Eur J Biochem (1980) 1.90
Vascular endothelial growth factor-C expression in human prostatic carcinoma and its relationship to lymph node metastasis. Br J Cancer (1999) 1.87
Congenital hereditary lymphedema caused by a mutation that inactivates VEGFR3 tyrosine kinase. Am J Hum Genet (2000) 1.86
Comparison of VEGF, VEGF-B, VEGF-C and Ang-1 mRNA regulation by serum, growth factors, oncoproteins and hypoxia. Oncogene (1997) 1.85
Two alternative mRNAs coding for the angiogenic factor, placenta growth factor (PlGF), are transcribed from a single gene of chromosome 14. Oncogene (1993) 1.83
Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation. Thromb Haemost (1998) 1.80
Structure, expression and receptor-binding properties of novel vascular endothelial growth factors. Curr Top Microbiol Immunol (1999) 1.79
Mutations and impaired function of LKB1 in familial and non-familial Peutz-Jeghers syndrome and a sporadic testicular cancer. Hum Mol Genet (1999) 1.79
Involvement of vascular endothelial growth factor receptor-3 in maintenance of integrity of endothelial cell lining during tumor angiogenesis. Blood (2000) 1.76
Signalling properties of FLT4, a proteolytically processed receptor tyrosine kinase related to two VEGF receptors. Oncogene (1994) 1.73
Adenoviral expression of vascular endothelial growth factor-C induces lymphangiogenesis in the skin. Circ Res (2001) 1.71
Enhanced jun gene expression is an early genomic response to transforming growth factor beta stimulation. Mol Cell Biol (1989) 1.70
Alternative forms of Max as enhancers or suppressors of Myc-ras cotransformation. Science (1992) 1.70
Expression of the vascular endothelial growth factor C receptor VEGFR-3 in lymphatic endothelium of the skin and in vascular tumors. Am J Pathol (1998) 1.66
Lipoprotein (a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants. Atherosclerosis (1991) 1.66
Enhanced expression of the tie receptor tyrosine kinase in endothelial cells during neovascularization. Blood (1992) 1.65
Characterization of surface glycoproteins of mouse lymphoid cells. J Cell Biol (1976) 1.64
Gene encoding a new RING-B-box-Coiled-coil protein is mutated in mulibrey nanism. Nat Genet (2000) 1.63
Expression of vascular endothelial growth factor receptor-3 and podoplanin suggests a lymphatic endothelial cell origin of Kaposi's sarcoma tumor cells. Lab Invest (1999) 1.62